Biotech IPOs surge to 31 in 2026, with four more companies queuing
Start here
Biotech companies are returning to public markets at a pace not seen since the 2021 boom. Thirty-one biotech firms have completed initial public offerings so far in 2026, according to BioSpace data, and another four have filed applications to follow. The 2026 total far exceeds the eight IPOs recorded in 2025 and also tops 2024 (19), 2023 (13) and 2022 (17). Even so, activity remains far below the nearly 100 debuts of 2021, the sector's peak year. With roughly two months of the year remaining and four filings pending, the final count could still rise, but the recovery has so far stopped well short of the previous cycle's highs.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- biospace.comPickBiotech notches 31 IPOs already this year, with 4 more joining queue
Thirty-one biotech companies have completed IPOs so far in 2026, with four more having filed to go public. BioSpace data show this total far exceeds 2025's eight IPOs and also tops 2024 (19), 2023 (13) and 2022 (17), though it remains far below the nearly 100 in 2021.
Heat trend for this story
Heat now 9·Peak in the comparable set 10 (Oct 23 00:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.